PharMerica Corporation Names Mark Lindemoen Senior Vice President of Sales and Client Services
LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today announced that Mark R. Lindemoen has joined the Company as Senior Vice President of Sales and Client Services. Mr. Lindemoen will report to Gregory S. Weishar, the Companys President and Chief Executive Officer. Mr. Lindemoen will be responsible for leading the Companys sales and client retention initiatives.
Mr. Lindemoen was most recently Vice President of Sales for Gulf South Medical Supply in Jacksonville, Florida. Prior to Gulf South, Mr. Lindemoen was the Vice President, Regional Segment Sales Health Systems for AmerisourceBergen in Thorofare, New Jersey, where he directed a $3.0 billion sales territory.
Mr. Lindemoen previously served as a vice president for McKesson Medical Surgical and SCA Incontinence Care in Atlanta.
Commenting on Mr. Lindemoens joining the Company, Gregory S. Weishar said, I am excited that Mark is leading our Sales and Client Service organization. He is a pharmaceutical sales veteran with many years of experience and the proven ability to take our sales and client retention efforts to the next level.
PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. PharMerica operates institutional pharmacies in 44 states. PharMericas customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect the Companys current estimates, expectations and projections about its future results, performance, prospects and opportunities. Forward-looking statements include, among other matters, statements regarding the amount and timing of share purchases and the method and manner in which the Company may implement its share purchase program. Forward-looking statements include statements that are not historical facts and can be identified by forward-looking words such as anticipate, believe, could, estimate, expect, intend, plan, may, should, will, would, project and similar expressions. These forward-looking statements are based upon information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause the Companys actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Important factors that could cause the Companys actual results to differ materially from the results referred to in the forward-looking statements we make in this press release are included in the Risk Factors section set forth in the Companys Annual Report on Form 10-K filed with the SEC and in other reports, including Quarterly Reports on Form 10-Q filed with the SEC by the Company.
You are cautioned not to place undue reliance on any forward-looking statements, all of which speak only as of the date of this press release. Except as required by law, we undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. All subsequent written and oral forward-looking statements attributable to us or any person acting on the Companys behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this press release and in the Risk Factors section set forth in the Companys Annual Report on Form 10-K filed with the SEC and in other reports filed with the SEC by the Company.
Michael J. Culotta, 502-627-7475
Executive Vice President and Chief Financial Officer
Source: PharMerica CorporationCopyright Business Wire 2012